On 14 March 2019, the CMA decided to close its investigation into pharmaceutical company MSD's discount scheme for the medicine Remicade, concluding that it was not likely to limit competition. Previously, the CMA had issued a statement of objections,
The UK Competition Authority decides to close its investigation into a pharmaceutical company’s discount scheme, concluding that it is not likely to limit competition (Remicade)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.